Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations

Blood

Volumn 103, Issue 2, 2004, Pages 375-382

  Damle, Rajendra N ^b   Batliwalla, Franak M ^b   Ghiotto, Fabio ^b   Valetto, Angelo ^b   Albesiano, Emilia ^b   Sison, Cristina ^b   Allen, Steven L ^b   Kolitz, Jonathan ^b   Vinciguerra, Vincent P ^b   Kudalkar, Prasad ^b   Wasil, Tarun ^b   Rai, Kanti R ^b   Ferrarini, Manlio ^b   Gregersen, Peter K ^b   Chiorazzi, Nicholas ^a  

^a N Shore Long Isl Jewish Res Inst ^*  (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD27 ANTIGEN; CD5 ANTIGEN; DNA; IMMUNOGLOBULIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M; PEPTIDE NUCLEIC ACID; TELOMERASE;

ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE; CELL DIVISION; CELL MATURATION; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN VARIABLE REGION; MAJOR CLINICAL STUDY; NEUTROPHIL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TELOMERE; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; TREATMENT OUTCOME;

EID: 9144245353     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-04-1345     Document Type: Article

References (54)

1. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994;8:1640-1645.
2. Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol. 1986;62:567-575.
3. Schroeder HW Jr, Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today. 1994;15:288-294.
4. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998;102:1515-1525.
5. Damle RN, Ghiotto F, Valetto A, et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood. 2002;99:4087-4093.
6. Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002;100:4609-4614.
7. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764-1775.
8. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840-1847.
9. H genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848-1854.
10. Chiorazzi N, Ferrarini M. B-cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Ann Rev Immunol. 2003;21:841-894.
11. Harley CB. Telomere loss: mitotic clock or genetic time bomb? Mutat Res. 1991;256:271-282.
12. Hayflick L, Moorhead PS. The limited in vitro lifespan of human diploid strains. Exp Cell Res. 1965;37:614-636.
13. Zhang X, Mar V, Zhou W, Harrington L, Robinson MO. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev. 1999;13:2388-2399.
14. Henderson S, Allsopp R, Spector D, Wang SS, Harley C. In situ analysis of changes in telomere size during replicative aging and cell transformation. J Cell Biol. 1996;134:1-12.
15. Notaro R, Cimmino A, Tabarini D, Rotoli B, Luzzatto L. In vivo telomere dynamics of human hematopoietic stem cells. Proc Natl Acad Sci U S A. 1997;94:13782-13785.
16. Hodes RJ. Telomere length, aging, and somatic cell turnover. J Exp Med. 1999;190:153-156.
17. Blackburn EH, Greider CW, Henderson E, Lee MS, Shampay J, Shippen-Lentz D. Recognition and elongation of telomeres by telomerase. Genome. 1989;31:553-560.
18. Nilsson P, Mehle C, Remes K, Roos G. Telomerase activity in vivo in human malignant hematopoietic cells. Oncogene. 1994;9:3043-3048.
19. Broccoli D, Young JW, de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci U S A. 1995;92:9082-9086.
20. Ely SA, Chadburn A, Dayton CM, Cesarman E, Knowles DM. Telomerase activity in B-cell non-Hodgkin lymphoma. Cancer. 2000;89:445-452.
21. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J. 1995;14:4240-4248.
22. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med. 1997;3:1271-1274.
23. Hu BT, Lee SC, Marin E, Ryan DH, Insel RA. Telomerase is up-regulated in human germinal center B cells in vivo and can be re-expressed in memory B cells activated in vitro. J Immunol. 1997;159:1068-1071.
24. Weng NP, Granger L, Hodes RJ. Telomere lengthening and telomerase activation during human B cell differentiation. Proc Natl Acad Sci U S A. 1997;94:10827-10832.
25. Norrback KF, Hultdin M, Dahlenborg K, Osterman P, Carlsson R, Roos G. Telomerase regulation and telomere dynamics in germinal centers. Eur J Haematol. 2001;67:309-317.
26. Batliwalla FM, Damle RN, Metz C, Chiorazzi N, Gregersen PK. Simultaneous flow cytometric analysis of cell surface markers and telomere length: analysis of human tonsilar B cells. J Immunol Methods. 2001;247:103-109.
27. Engelhardt M, Albanell J, Drullinsky P, et al. Relative contribution of normal and neoplastic cells determines telomerase activity and telomere length in primary cancers of the prostate, colon, and sarcoma. Clin Cancer Res. 1997;3:1849-1857.
28. Bechter OE, Eisterer W, Pall G, Hilbe W, Kuhr T, Thaler J. Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia. Cancer Res. 1998;58:4918-4922.
29. Damle RN, Batliwalla FM, Albesiano E, et al. Telomere length analysis suggests distinct replicative histories of B-CLL subgroups [abstract]. Blood. 2000;96:836a.
30. Damle RN, Fais F, Ghiotto F, et al. Chronic lymphocytic leukemia: a proliferation of B cells at two distinct stages of differentiation. Curr Top Microbiol Immunol. 2000;252:285-293.
31. Rufer N, Dragowska W, Thornbury G, Roosnek E, Lansdorp PM. Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry. Nat Biotechnol. 1998;16:743-747.
32. Buchardt O, Egholm M, Berg RH, Nielsen PE. Peptide nucleic acids and their potential applications in biotechnology. Trends Biotechnol. 1993;11:384-386.
33. Kim NW, Wu F. Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). Nucleic Acids Res. 1997;25:2595-2597.
34. Son NH, Murray S, Yanovski J, Hodes RJ, Weng N. Lineage-specific telomere shortening and unaltered capacity for telomerase expression in human T and B lymphocytes with age. J Immunol. 2000;165:1191-1196.
35. Serrano D, Monteiro J, Allen SL, et al. Clonal expansion within the CD4+CD57+ and CD8+CD57+ T cell subsets in chronic lymphocytic leukemia. J Immunol. 1997;158:1482-1489.
36. Perry S, Moxley JH 3rd, Weiss GH, Zelen M. Studies of leukocyte kinetics by liquid scintillation counting in normal individuals and in patients with chronic myelocytic leukemia. J Clin Invest. 1966;45:1388-1399.
37. Wellinger RJ, Wolf AJ, Zakian VA. Use of nondenaturing Southern hybridization and two dimensional agarose gels to detect putative intermediates in telomere replication in Saccharomyces cerevisiae. Chromosoma. 1992;102:S150-S156.
38. Ishibe N, Prieto D, Hosack DA, et al. Telomere length and heavy-chain mutation status in familial chronic lymphocytic leukemia. Leuk Res. 2002;26:791-794.
39. Hultdin M, Rosenquist R, Thunberg U, et al. Association between telomere length and V(H) gene mutation status in chronic lymphocytic leukaemia: clinical and biological implications. Br J Cancer. 2003;88:593-598.
40. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011-2015.
41. Igarashi H, Sakaguchi N. Telomerase activity is induced in human peripheral B lymphocytes by the stimulation to antigen receptor. Blood. 1997;89:1299-1307.
42. Dighiero G, Kipps T, Schroeder HW, et al. What is the CLL B-lymphocyte? Leuk Lymphoma. 1996;22:13-39.
43. Jurlander J. The cellular biology of B-cell chronic lymphocytic leukemia. Crit Rev Oncol Hematol. 1998;27:29-52.
44. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194:1639-1647.
45. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194:1625-1638.
46. Stephenson CF, Desai ZR, Bridges JM. The proliferative activity of B-chronic lymphocytic leukaemia lymphocytes prior to and after stimulation with TPA and PHA. Leuk Res. 1991;15:1005-1012.
47. Caligaris-Cappio F, Gottardi D, Alfarano A, et al. The nature of the B lymphocyte in B-chronic lymphocytic leukemia. Blood Cells. 1993;19:601-613.
48. Wang D, Wells SM, Stall AM, Kabat EA. Reaction of germinal centers in the T-cell-independent response to the bacterial polysaccharide alpha(1->6)dextran. Proc Natl Acad Sci U S A. 1994;91:2502-2506.]
49. Vinuesa CG, Sze DM, Cook MC, et al. Recirculating and germinal center B cells differentiate into cells responsive to polysaccharide antigens. Eur J Immunol. 2003;33:297-305.
50. Messmer BT, Messmer D, Allen SL, Kudalkar P, Rai KR, Chiorazzi N. Three subsets of chronic lymphocytic leukemia defined by gene expression profiling [abstract]. Blood. 2003;100:378.
51. Murnane JP, Sabatier L, Marder BA, Morgan WR. Telomere dynamics in an immortal human cell line. EMBO J. 1994;13:4953-4962.
52. Ogino H, Nakabayashi K, Suzuki M, et al. Release of telomeric DNA from chromosomes in immortal human cells lacking telomerase activity. Biochem Biophys Res Commun. 1998;248:223-227.
53. Yeager TR, Neumann AA, Englezou A, Huschtscha LI, Noble JR, Reddel RR. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res. 1999;59:4175-4179.
54. Trentin L, Ballon G, Ometto L, et al. Telomerase activity in chronic lymphoproliferative disorders of B-cell lineage. Br J Haematol. 1999;106:662-668.